Dec 09, 2020 04:20 PM EST
Pfizer Inc. announced that the Food and Drug Association (FDA) granted priority review to its biologics license application that seeks approval for its 20-valent pneumococcal conjugate vaccines for adults.
According to NASDAQ, the FDA granted priority review, which is expected to release in June 2021. Pfizer's v includes 13 serotypes in its well-known 13-valent pneumococcal conjugate vaccine, seven serotypes, and Prevnar 13.
Meanwhile, Merck (MRK) is in the process of developing a 15-valent pneumococcal conjugate vaccine candidate in late-stage studies. Merck's phase III clinical development program includes 16 late-stage studies that will evaluate the vaccine candidate in different populations who are at a higher risk for pneumococcal disease.
This year, Pfizer's shares rose to 8.6% compared with the industry's 2.8% increase. The share price increased primarily because of Pfizer and its Germany-based partner BioNTech's rapid development and regulatory plans for its COVID-19 vaccine candidate.
In the United Kingdom and Bahrain, the COVID-19 two-shot vaccine was approved for emergency use this month. The drugmaker giant also filed for emergency use in the U.S., India, and E.u. Besides, the companies initiated rolling submissions with Australia, Japan, and Canada regulatory agencies.
In the past month, Pfizer stock increased to more than 20% on the enthusiasm that it will be the first drugmaker to bring scientifically validated COVID-19 vaccine worldwide. Pfizer's commercialization efforts also generated tens of billions of dollars in potential revenue, as per The Motley Fool via MSN.
Many investors are aiming to get rich off of Pfizer's stock with its shares gaining momentum. However, Pfizer and BioNTech's messenger RNA coronavirus vaccine achieved 95% efficacy in late-stage last month.
Initially, Pfizer's COVID-19 vaccine was initiated to patients in the U.K. and is awaiting EUA by the FDA and approval by the European Medical Agency. Pfizer is expected to make 50 million doses of COVID-19 vaccines and another 1.3 billion by the end of 2021.
There is a lot of revenue potential at the price tag of $19.5. Aside from that, Pfizer; score operations perform handsomely, as per Motley Fool. On November 16, the drugmaker giant completed the generic drug business Upjohn's spin-off to form Viatris.
This year, Upjohn's revenue dropped by 18% for more than a year as the FDA approved a record number for generics as an initiative to crack down high drug pricing. Pfizer's core business is currently consisted of brand name oncological drugs, anti-infectious disease treatments, cardiovascular treatments,, and biosimilars.
During its biopharma sales grew by 4% compared to 2019 with $10.2 billion. For the full year, the new Pfizer expects to bring in $42.4 billion in sales and $2.38 in earnings per share. The company projects can grow its revenue to more than 6% yearly from now through 2025.
Journalists love their jobs because they get to interact with people from all sorts of backgrounds and expertises, then turn around and share their knowledge with the world.
As the metaverse takes over more of our digital lives, the commoditization of all aspects of our virtual beings becomes more and more of a reality.
Rustam Gilfanov is a famous IT businessman, a founder of a large IT company, and a partner of the LongeVC Fund.
Bitcoin and cryptocurrency in general guarantee some amazing profits if invested correctly.
In the currency trading business, many individuals make mistakes. Since most individuals join this profession with too much excitement, they forget about efficient strategies. Instead of controlling their investment and execution process, most individuals make poor choices for trading.
In today's digital world, more and more people are investing in cryptocurrencies. These digital tokens have exploded into popularity over the past few years, and have grown to the point that there are now nearly over 6,000 of them, according to Statista.
Following the pandemic, natural calamities, and major employment shifts, a startling new study on the online news site News Nation shows that 1 in 4 Americans don't have an emergency fund.
Generational wealth is a facet of wealth management that is often misunderstood. Labeled trust fund babies, rich kids, and lucky breaks, those who receive an inheritance from families are rare.
Social media has successfully made it to the mainstream consciousness of over half the global population. DataReportal's latest study shows that over 4.33 billion people worldwide are using some form of social networking site this year. That's why it's no wonder many tech companies are interested in investing or forming the next Facebook, Twitter, or YouTube to capture the hearts and minds of the general population.
Ease of access, freedom to choose in which to invest the money and lines of credit designed according to the needs of consumers, are some of the characteristics that have made consumer credit one of the most important financing products in the world’s market.